-
公开(公告)号：US20090088559A1
公开(公告)日：2009-04-02
申请号：US12011979
申请日：2008-01-30
IPC分类号： C07K14/00
CPC分类号： C12N15/1058 , C07K1/107 , C07K14/31 , C07K19/00 , C12N15/1034
摘要： Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest, b) screening the polypeptides expressed in step a) for function, immunogenicity and/or stability, c) selecting functional polypeptides having altered immunogenicity and/or increased stability, e.g. functional in vivo half-life as compared to the polypeptide of interest, and d) optionally subjecting the nucleotide sequence encoding the polypeptide selected in step c) to one or more repeated cycles of steps a)-c). In a further step the expressed polypeptides of step a) or c) can be conjugated to at least one non-polypeptide moiety.
摘要翻译： 公开了产生具有改变的免疫原性或改善的稳定性的多肽的方法。 所述方法包括：a）表达编码感兴趣多肽的核苷酸序列的多样化群体，b）筛选功能，免疫原性和/或稳定性在步骤a）中表达的多肽，c）选择具有改变的免疫原性和/或增加稳定性的功能性多肽 ，例如 与目的多肽相比具有功能的体内半衰期，和d）任选地将编码步骤c）中选择的多肽的核苷酸序列经历步骤a）-c）的一个或多个重复循环。 在另一步骤中，步骤a）或c）的表达多肽可以与至少一个非多肽部分缀合。
-
公开(公告)号：US20090017007A1
公开(公告)日：2009-01-15
申请号：US11995866
申请日：2006-08-23
申请人： Kim Vilbour Andersen
发明人： Kim Vilbour Andersen
CPC分类号： A61K45/06 , A61K33/30 , A61K38/36 , A61K38/4846 , A61K47/02 , A61K2300/00
摘要： Storage-stable aqueous pharmaceutical compositions comprising a Factor VII or Factor Vila polypeptide, a buffering agent, and zinc ions (Zn2+) as a stabilizer.
摘要翻译： 包含因子VII或因子VIIa多肽，缓冲剂和锌离子（Zn 2+）作为稳定剂的储存稳定的水性药物组合物。
-
公开(公告)号：US07144574B2
公开(公告)日：2006-12-05
申请号：US10084706
申请日：2002-02-26
CPC分类号： B82Y5/00 , A61K9/0019 , A61K31/724 , A61K38/21 , A61K38/215 , A61K47/40 , A61K47/6951 , C07K14/565 , A61K2300/00
摘要： The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.
摘要翻译： 本发明涉及一种表现出干扰素β（IFNB）活性的缀合物，其包含共价连接到IFNB多肽的至少一个第一非多肽部分，所述第一非多肽部分与至少一个引入的和在 至少一个除去的氨基酸残基，其包含所述第一非多肽部分的连接基团。 第一非多肽部分是例如。 聚合物分子或糖部分。 该缀合物在治疗中特别有用。 本发明还涉及包含至少一个体内糖基化位点的母体IFNB多肽的糖基化变体，其中位于所述糖基化位点附近的所述亲本多肽的氨基酸残基已被修饰以获得具有增加的糖基化的变体多肽作为 与母体多肽的糖基化相比。
-
公开(公告)号：US06806063B2
公开(公告)日：2004-10-19
申请号：US09782587
申请日：2001-02-12
IPC分类号： A61K3836
CPC分类号： C07K14/745 , A61K38/00 , A61K47/60 , A61K47/62 , C12N9/6437 , C12Y304/21021 , Y10S514/802
摘要： Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
摘要翻译： 提供因子VII（FVII）和因子VIIa（FVIIA）的缀合物，以及制备它们的方法。 提供了有助于制备这种缀合物的新型多肽的制备方法。 提供了通过施用FVII或FVIIa缀合物治疗的方法。
-
公开(公告)号：US06646110B2
公开(公告)日：2003-11-11
申请号：US09760008
申请日：2001-01-10
申请人： Torben Lauesgaard Nissen , Kim Vilbour Andersen , Christian Karsten Hansen , Jan Moller Mikkelsen , Hans Thalsgard Schambye
发明人： Torben Lauesgaard Nissen , Kim Vilbour Andersen , Christian Karsten Hansen , Jan Moller Mikkelsen , Hans Thalsgard Schambye
IPC分类号： C07K100
CPC分类号： A61K9/0019 , A61K38/00 , A61K47/42 , C07K14/535
摘要： The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g., be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g., be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate has one or more improved properties such as increased biological half-life and reduced side effects.
摘要翻译： 本发明涉及多肽缀合物，其包含显示G-CSF活性的多肽，并且具有不同于至少一个指定的引入和/或去除的氨基酸残基中的人G-CSF的氨基酸序列的氨基酸序列，所述氨基酸残基包含用于 非多肽部分，并且具有连接到多肽的连接基团的至少一个非多肽部分。 连接基团可以例如是赖氨酸，半胱氨酸，天冬氨酸或谷氨酸残基或糖基化位点，并且非多肽部分可以例如是聚合物，例如聚乙二醇或低聚糖。 缀合物具有一个或多个改进的性质，例如增加的生物半衰期和减少的副作用。
-
公开(公告)号：US20140228292A1
公开(公告)日：2014-08-14
申请号：US14233455
申请日：2012-07-09
CPC分类号： A61K47/48284 , A61K38/24 , A61K47/60 , A61K47/643 , A61K47/644 , A61K47/68 , C07K14/59 , C07K14/76 , C07K2319/31
摘要： The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilisation, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.
摘要翻译： 本发明涉及一种长效生物活性黄体生成激素（LH）化合物，其包含与药学上可接受的分子连接的LH激动剂，所述LH激动剂提供LH激动剂或LH化合物的体内血浆半衰期，其与体内相比大大增加 以与LH化合物相同的方式施用LH激动剂的血浆半衰期。 本发明涉及用于受控卵巢刺激的方法，其可以与辅助生殖技术如体外受精，细胞内精子注射，子宫内子宫内受精和体外成熟结合使用。 在其他方面，本发明涉及诱导卵泡发生的方法以及为黄体提供黄体支持的方法。
-
公开(公告)号：US20100260741A1
公开(公告)日：2010-10-14
申请号：US12707453
申请日：2010-02-17
CPC分类号： C12N9/6437 , A61K38/00 , C12Y304/21021
摘要： The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.
摘要翻译： 本发明涉及因子VII（FVII）或因子VIIa（FVIIa）多肽的新型多肽变体，其中所述变体包含位置10和32的氨基酸取代，并且其中所述变体还包含共价连接到引入 位于Gla结构域之外的体内N-糖基化位点。 这样的多肽变体可用于治疗，特别是用于治疗各种凝血相关疾病如创伤。
-
公开(公告)号：US07700733B2
公开(公告)日：2010-04-20
申请号：US10512754
申请日：2003-04-29
IPC分类号： A61K35/14
CPC分类号： C12N9/6437 , A61K38/00 , C12Y304/21021
摘要： The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.
摘要翻译： 本发明涉及因子VII（FVII）或因子VIIa（FVIIa）多肽的新型多肽变体，其中所述变体包含位置10和32的氨基酸取代，并且其中所述变体还包含共价连接到引入 位于Gla结构域之外的体内N-糖基化位点。 这样的多肽变体可用于治疗，特别是用于治疗各种凝血相关疾病如创伤。
-
公开(公告)号：US07511024B2
公开(公告)日：2009-03-31
申请号：US11279541
申请日：2006-04-12
IPC分类号： C07H21/04
CPC分类号： C07K14/745 , A61K38/00 , A61K47/60 , A61K47/62 , C12N9/6437 , C12Y304/21021 , Y10S514/802
摘要： Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
摘要翻译： 提供因子VII（FVII）和因子VIIa（FVIIA）的缀合物，以及制备它们的方法。 提供了有助于制备这种缀合物的新型多肽的制备方法。 提供了通过施用FVII或FVIIa缀合物治疗的方法。
-
公开(公告)号：US07442524B2
公开(公告)日：2008-10-28
申请号：US11423662
申请日：2006-06-12
IPC分类号： C07K14/745
CPC分类号： C07K14/745 , A61K38/00 , A61K47/60 , A61K47/62 , C12N9/6437 , C12Y304/21021 , Y10S514/802
摘要： Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
-
-
-
-
-
-
-
-
-
搜索结果
61 条记录 (耗时 0.04 秒)
